T

Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119

Watchlist Manager
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Watchlist
Price: 18.48 CNY -3.25%
Market Cap: 8.6B CNY
Have any thoughts about
Tianjin Ringpu Bio-Technology Co Ltd?
Write Note

Operating Margin
Tianjin Ringpu Bio-Technology Co Ltd

16.7%
Current
18%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
16.7%
=
Operating Profit
403.3m
/
Revenue
2.4B

Operating Margin Across Competitors

Country CN
Market Cap 8.6B CNY
Operating Margin
17%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 756.3B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 349.7B USD
Operating Margin
28%
Country US
Market Cap 251.6B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.6B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 151.4B USD
Operating Margin
22%
No Stocks Found

Tianjin Ringpu Bio-Technology Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Tianjin Ringpu Bio-Technology Co., Ltd. has carved a niche for itself as a formidable player in the animal health and nutrition industry. Founded in 1998, the company has steadily expanded its portfolio, offering a diverse range of products designed to enhance the health and productivity of livestock and pets. Ringpu's operations are tightly integrated across research, development, production, and sales of veterinary vaccines, medicines, and feed additives. By leveraging cutting-edge biotechnology, Ringpu devises innovative solutions that meet the rigorous standards of animal health care. Its research facilities are at the forefront of developing vaccines that guard against prevalent livestock and pet diseases, ensuring that its offerings remain both effective and relevant. The company's ability to generate revenue hinges on its extensive distribution network and the strategic partnerships it has fostered within China and globally. Ringpu sells its products through a well-established sales force that connects with farmers, livestock producers, and veterinary clinics, providing not just products but also comprehensive health management solutions. Additionally, the company invests heavily in fostering relationships with academic institutions and research bodies, ensuring a steady pipeline of groundbreaking discoveries and innovations. This approach not only bolsters the company's reputation in the industry but also guarantees a sustained stream of income as more clients turn to Ringpu for reliable and sophisticated animal healthcare solutions.

Intrinsic Value
24.96 CNY
Undervaluation 26%
Intrinsic Value
Price
T

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
16.7%
=
Operating Profit
403.3m
/
Revenue
2.4B
What is the Operating Margin of Tianjin Ringpu Bio-Technology Co Ltd?

Based on Tianjin Ringpu Bio-Technology Co Ltd's most recent financial statements, the company has Operating Margin of 16.7%.